Janux Therapeutics, Inc. (JANX) 10-Year Financial Performance & Capital Metrics

JANX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutJanux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.Show more

Revenue $11M +31.0%
EBITDA -$97M -36.3%
Net Income -$69M -18.4%
EPS (Diluted) -1.28 +3.0%
Gross Margin 80.54% +6.2%
EBITDA Margin -914.12% -4.0%
Operating Margin -933.58% -3.4%
Net Margin -651.62% +9.6%
ROE -10.09% +42.4%
ROIC -15.37% +9.6%
Debt/Equity 0.02 -68.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.7x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Shares diluted 22.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y42.79%

TTM-23.37%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-68.32%

EPS CAGR

10Y-

5Y-

3Y-

TTM-43.59%

ROCE

10Y Avg-35.42%

5Y Avg-35.42%

3Y Avg-17.73%

Latest-14.01%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	3.64M	8.61M	8.08M	10.59M
Revenue Growth %	-	-	-	1.37%	-0.06%	0.31%
Cost of Goods Sold+	6K	13K	0	841K	1.96M	2.06M
COGS % of Revenue	-	-	-	0.1%	0.24%	0.19%
Gross Profit+	-6K	-13K	3.64M	7.77M	6.13M	8.53M
Gross Margin %	-	-	1%	0.9%	0.76%	0.81%
Gross Profit Growth %	-	-1.17%	280.77%	1.14%	-0.21%	0.39%
Operating Expenses+	3.77M	4.83M	36.57M	74.86M	79.11M	107.38M
OpEx % of Revenue	-	-	10.05%	8.69%	9.79%	10.14%
Selling, General & Admin	772K	1.79M	10.33M	22.26M	26.14M	41.05M
SG&A % of Revenue	-	-	2.84%	2.58%	3.23%	3.88%
Research & Development	3M	3.04M	26.24M	53.44M	54.92M	68.39M
R&D % of Revenue	-	-	7.21%	6.21%	6.79%	6.46%
Other Operating Expenses	0	0	0	-841K	-1.96M	-2.06M
Operating Income+	-3.77M	-4.84M	-32.93M	-67.09M	-72.98M	-98.85M
Operating Margin %	-	-	-9.05%	-7.79%	-9.03%	-9.34%
Operating Income Growth %	-	-0.28%	-5.8%	-1.04%	-0.09%	-0.35%
EBITDA+	-3.77M	-4.83M	-32.82M	-66.25M	-71.02M	-96.79M
EBITDA Margin %	-	-	-9.02%	-7.69%	-8.79%	-9.14%
EBITDA Growth %	-	-0.28%	-5.79%	-1.02%	-0.07%	-0.36%
D&A (Non-Cash Add-back)	6K	13K	113K	841K	1.96M	2.06M
EBIT	-3.77M	-6.58M	-32.93M	-67.09M	-72.98M	-98.85M
Net Interest Income+	0	0	257K	4.03M	14.69M	29.85M
Interest Income	233K	206K	257K	4.03M	14.69M	29.85M
Interest Expense	233K	206K	0	0	0	0
Other Income/Expense	-233K	-1.94M	257K	4.03M	14.69M	29.85M
Pretax Income+	-4M	-6.78M	-32.67M	-63.06M	-58.29M	-68.99M
Pretax Margin %	-	-	-8.98%	-7.32%	-7.21%	-6.52%
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1.06%	1%	1%	1%	1%	1%
Net Income+	-4.24M	-6.78M	-32.67M	-63.06M	-58.29M	-68.99M
Net Margin %	-	-	-8.98%	-7.32%	-7.21%	-6.52%
Net Income Growth %	-	-0.6%	-3.82%	-0.93%	0.08%	-0.18%
Net Income (Continuing)	-4M	-6.78M	-32.67M	-63.06M	-58.29M	-68.99M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.10	-0.16	-0.79	-1.52	-1.32	-1.28
EPS Growth %	-	-0.6%	-3.94%	-0.92%	0.13%	0.03%
EPS (Basic)	-0.10	-0.16	-0.79	-1.52	-1.32	-1.28
Diluted Shares Outstanding	41.61M	41.61M	41.24M	41.47M	44.02M	53.75M
Basic Shares Outstanding	41.61M	41.61M	41.24M	41.47M	44.02M	53.75M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	658K	16.06M	377.02M	332.44M	349.24M	1.03B
Cash & Short-Term Investments	658K	7.81M	374.96M	327.02M	344.03M	1.03B
Cash Only	658K	7.81M	35.58M	51.43M	19.2M	430.61M
Short-Term Investments	0	0	339.38M	275.59M	324.82M	594.57M
Accounts Receivable	0	8M	0	700K	0	5.38M
Days Sales Outstanding	-	-	-	29.67	-	185.5
Inventory	0	0	0	-700K	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	5.42M	5.21M	0
Total Non-Current Assets+	21K	155K	2.81M	31.57M	31.17M	27.85M
Property, Plant & Equipment	21K	155K	1.6M	29.36M	27.84M	24.15M
Fixed Asset Turnover	-	-	2.28x	0.29x	0.29x	0.44x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	816K	0	0
Other Non-Current Assets	0	0	1.21M	1.39M	3.33M	3.7M
Total Assets+	679K	16.22M	379.82M	364.01M	380.41M	1.06B
Asset Turnover	-	-	0.01x	0.02x	0.02x	0.01x
Asset Growth %	-	22.88%	22.42%	-0.04%	0.05%	1.79%
Total Current Liabilities+	4.63M	3.18M	12.8M	16.51M	13.03M	17.46M
Accounts Payable	267K	428K	2.46M	2.16M	2.42M	4.03M
Days Payables Outstanding	16.24K	12.02K	-	937.02	452.56	713.34
Short-Term Debt	4M	0	0	0	0	0
Deferred Revenue (Current)	0	1000K	1000K	1000K	1000K	0
Other Current Liabilities	82K	338K	2.37M	5.51M	3.3M	11.68M
Current Ratio	0.14x	5.05x	29.46x	20.14x	26.80x	59.21x
Quick Ratio	0.14x	5.05x	29.46x	20.18x	26.80x	59.21x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	4M	27.67M	700K	26.76M	23.02M	21.28M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	24.54M	23.02M	21.28M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	4M	21.62M	0	0	0	0
Total Liabilities	8.62M	30.86M	13.5M	43.27M	36.06M	38.73M
Total Debt+	4M	0	194K	25.3M	24.54M	23.02M
Net Debt	3.34M	-7.81M	-35.39M	-26.12M	5.34M	-407.58M
Debt / Equity	-	-	0.00x	0.08x	0.07x	0.02x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-16.18x	-23.51x	-	-	-	-
Total Equity+	-7.94M	-14.64M	366.33M	320.74M	344.35M	1.02B
Equity Growth %	-	-0.84%	26.03%	-0.12%	0.07%	1.97%
Book Value per Share	-0.19	-0.35	8.88	7.73	7.82	19.03
Total Shareholders' Equity	-7.94M	-14.64M	366.33M	320.74M	344.35M	1.02B
Common Stock	1K	1K	41K	42K	46K	59K
Retained Earnings	-7.96M	-14.74M	-47.41M	-110.47M	-168.76M	-237.76M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	-270K	-1.53M	665K	2.16M
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.83M	-4.37M	-16.98M	-42.92M	-50.58M	-43.81M
Operating CF Margin %	-	-	-4.67%	-4.98%	-6.26%	-4.14%
Operating CF Growth %	-	-0.14%	-2.89%	-1.53%	-0.18%	0.13%
Net Income	-4M	-6.78M	-32.67M	-63.06M	-58.29M	-68.99M
Depreciation & Amortization	6K	13K	113K	841K	1.96M	2.06M
Stock-Based Compensation	6K	72K	6.91M	17.2M	20M	33.02M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	233K	1.94M	-169K	-2.18M	-7.69M	-10.59M
Working Capital Changes	-69K	389K	8.84M	4.28M	-6.55M	685K
Change in Receivables	0	-8M	8M	0	0	0
Change in Inventory	0	0	831K	0	0	0
Change in Payables	4K	14K	2.14M	-294K	277K	1.58M
Cash from Investing+	0	0	-340.96M	58.27M	-41.19M	-258.02M
Capital Expenditures	0	0	-1.48M	-6.45M	-1.85M	-359K
CapEx % of Revenue	-	-	0.41%	0.75%	0.23%	0.03%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	-339.48M	64.71M	0	0
Cash from Financing+	4M	11.52M	386.52M	500K	59.55M	713.24M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	70K	1.81M	0	3.02M	14.97M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-3.83M	-4.37M	-18.46M	-49.37M	-52.42M	-44.17M
FCF Margin %	-	-	-5.08%	-5.73%	-6.49%	-4.17%
FCF Growth %	-	-0.14%	-3.22%	-1.67%	-0.06%	0.16%
FCF per Share	-0.09	-0.10	-0.45	-1.19	-1.19	-0.82
FCF Conversion (FCF/Net Income)	0.90x	0.64x	0.52x	0.68x	0.87x	0.64x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-18.58%	-18.36%	-17.53%	-10.09%
Return on Invested Capital (ROIC)	-	-	-16.01%	-16.09%	-16.99%	-15.37%
Gross Margin	-	-	100%	90.23%	75.81%	80.54%
Net Margin	-	-	-898.32%	-732.22%	-721.18%	-651.62%
Debt / Equity	-	-	0.00x	0.08x	0.07x	0.02x
Interest Coverage	-16.18x	-23.51x	-	-	-	-
FCF Conversion	0.90x	0.64x	0.52x	0.68x	0.87x	0.64x
Revenue Growth	-	-	-	136.79%	-6.14%	30.99%

Frequently Asked Questions

Growth & Financials

Janux Therapeutics, Inc. (JANX) reported $10.0M in revenue for fiscal year 2024.

Janux Therapeutics, Inc. (JANX) grew revenue by 31.0% over the past year. This is strong growth.

Janux Therapeutics, Inc. (JANX) reported a net loss of $101.9M for fiscal year 2024.

Dividend & Returns

Janux Therapeutics, Inc. (JANX) has a return on equity (ROE) of -10.1%. Negative ROE indicates the company is unprofitable.

Janux Therapeutics, Inc. (JANX) had negative free cash flow of $71.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener